Evidence and identity guide · Sources checked October 18, 2026
The short answer
In a CJC-1295 listing, No DAC means without the drug affinity complex, the albumin-binding modification associated with long-acting CJC-1295. It is a chemical-identity distinction, not simply a different package size. The long-acting compound studied in widely cited human trials cannot be treated as proof of the behavior of a material labeled No DAC.
The useful question is therefore not “Which name sounds more familiar?” It is “Does the compound in this paper match the compound in this listing?” This guide explains how to answer that question without borrowing results from a different preparation.
What the extra modification changes
The original CJC-1295 development work examined growth-hormone-releasing-factor analogues designed to associate covalently with albumin. Albumin is a circulating protein; attaching a compound to it is a chemical strategy for changing its persistence. The 2005 study by Jetté and colleagues reported albumin-associated material and biological activity in rat experiments. That paper helps explain the design of the long-acting analogue, but it is not an analysis of a modern retail vial. Read the original bioconjugate study.
Removing an identity-defining modification does not leave every experimental property unchanged. A shared backbone or similar commercial name is a reason to investigate a relationship, not a reason to assume equivalence. Neither the letters DAC nor their absence establish a particular product’s purity, stability or suitability.
Which CJC-1295 did the human study examine?
Teichman and colleagues’ 2006 publication describes long-acting CJC-1295 in healthy adults. Its trials examined pharmacokinetics and changes in growth hormone and IGF-I, among other study observations. The preparation was developed for extended action; the study does not identify Dissolv’s No DAC listing as its test material. Read the clinical pharmacology paper.
Keep the endpoint attached to the finding. A measured hormone response is not automatically evidence of improved sleep, recovery, appearance or longevity. Similarly, a duration reported for the studied preparation should not become a duration claim for a different chemical form. This article intentionally gives no No DAC half-life estimate or administration advice.
Salt form and DAC are separate questions
FDA’s December 2024 presentation considered CJC-1295-related substances as distinct forms, including forms with DAC and without it. The presentation also noted limits in the available evidence for the non-DAC forms and uncertainty about salt forms in clinical references. Those distinctions are useful when reading a name, even though the presentation does not authenticate a supplier’s material. See the FDA presentation, CJC-1295 section.
Do not collapse “acetate,” “free base,” and “No DAC” into one interchangeable label. One describes a form of the material; another addresses the additional modification. A short product title may omit information required for an experimental comparison.
A practical identity check before citing a paper
- Copy the complete name. Include No DAC or DAC rather than shortening everything to CJC.
- Find the structural description. Compare sequence and modifications where documented. Do not infer them solely from the title.
- Record the form. Note the salt or counterion if supplied. Mark missing information as unknown.
- Match the actual experiment. Record species or participant group, preparation and measured endpoint.
- Separate the commercial lot. A publication about a compound is not a certificate for the material being purchased.
This checklist can be used as a reading worksheet: one column for the listing, another for the publication, and a third for unresolved differences. A blank cell is useful information. It tells you which fact must be verified before the comparison can support a conclusion.
Common questions
Is No DAC the same as a lower amount of DAC?
No. The wording describes absence of the modification, not a reduction in the amount of an otherwise identical compound.
Does a No DAC label establish the exact sequence?
No. It narrows the intended identity but does not replace the full specification and analytical documentation.
Can a CJC-1295 trial validate a combination product?
Not on its own. Adding another component creates a different preparation and research question. Neither the shared name nor separate ingredient papers establish the behavior of that combination.
Find the named research material
Dissolv lists CJC-1295 (No DAC) 5mg. The number in the listing describes the labeled presentation, not a recommended dose. Confirm the exact chemical form and current lot documentation before deciding whether it matches an authorized laboratory project.
For laboratory research only. Not for human or veterinary use. This link does not imply therapeutic suitability, clinical equivalence or independent verification of the supplied lot.
Sources
- Jetté et al., 2005: identification of CJC-1295 as a long-lasting GRF analogue
- Teichman et al., 2006: long-acting CJC-1295 clinical pharmacology
- FDA December 4, 2024 PCAC presentation, CJC-1295 section
Educational synthesis prepared with AI assistance. This is not a systematic review or medical advice. Product links lead to Dissolv’s own catalog.
